P-bi-TAT

P-bi-TAT is an investigational **anticancer thyrointegrin antagonist** being developed by NanoPharmaceuticals. It is a **PEGylated small-molecule conjugate** composed of two tetraiodothyroacetic acid molecules linked to polyethylene glycol, giving a molecular weight greater than 3000 Da. The agent is designed to bind the **integrin alphaV beta3** receptor on tumor cells and tumor vasculature, where it antagonizes thyroid hormone analog signaling and modulates cancer-relevant transcriptional programs. In preclinical studies, P-bi-TAT has shown antitumor activity in glioblastoma multiforme, pancreatic cancer, and other human cancer models, including effects on cancer stemness, proliferation, survival, angiogenesis, and tumor energy metabolism, with reported downregulation of genes involved in electron transport and oxidative phosphorylation. It has also been described as crossing the blood-brain barrier, supporting potential use in brain cancers such as glioblastoma.

Other names

polyethylene glycol conjugated bivalent tetraiodothyroacetic acidPEGylated bivalent tetrac